---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-041524"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2023-11-15T23:59:59+00:00"
generated_at: "2026-06-08T02:34:47.134232+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# bioAffinity Q3 revenue surges to $298K on PPLS acquisition; net loss narrows to $2.3M

## Summary
- Revenue of $298,484 for Q3 2023, up from $1,150 in prior year, primarily from acquired PPLS lab.
- Net loss of $2.3M ($0.26 per share) vs $4.9M ($1.17) in prior year; cash at $4.5M down from $11.4M.
- Acquired non-medical assets of Village Oaks Pathology Services on Sept 18, 2023; PPLS forecast to contribute $8.7M net revenue over next 12 months.
- CMS issued preliminary payment decision for CyPath Lung; final expected Nov 2023 with effective date Jan 1, 2024.
- Revenue outlook for full year 2023: $2.1-$2.3M; next 12 months: $8.4-$9.0M.

## SEC filing metadata
- accession: 0001493152-23-041524
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2023-11-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315223041524/0001493152-23-041524-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315223041524/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-041524
- JSON: https://secwatch.observer/filing/0001493152-23-041524.json
- Plain text: https://secwatch.observer/filing/0001493152-23-041524.txt

## Key facts
- Earnings Releases
  bioAffinity Technologies, Inc. reported financial results for quarter ended September 30, 2023.
  - Period: quarter ended September 30, 2023
  - Result: reported results
  source text: On November 14, 2023, bioAffinity Technologies, Inc., a Delaware corporation (the "Registrant"), issued a press release that included financial information for its quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1712762/000149315223041524/0001493152-23-041524-index.htm
- Earnings Releases
  bioAffinity Technologies, Inc. reported three and nine months ended Sept. 30, 2023 results: revenue $298,484, EPS $0.26 per share. Guidance reaffirmed.
  - Period: three and nine months ended Sept. 30, 2023
  - Revenue: $298,484
  - EPS: $0.26 per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: with larger medical systems, we anticipate substantial revenue growth for CyPath ® Lung.” Third Quarter Financial Results Revenue for the third quarter of 2023 increased to $298,484, up from $1,150 in the prior-year period. Prior to the Sept. 18, 2023, acquisition of PPLS, bioAffinity Technologies’ revenue was generated from royalties from sales of CyPath ®
  evidence_url: https://www.sec.gov/Archives/edgar/data/1712762/000149315223041524/0001493152-23-041524-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.